Please ensure Javascript is enabled for purposes of website accessibility

What Happened in the Stock Market Today

By Jim Crumly - Jun 24, 2019 at 4:55PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

El Dorado and Caesars Entertainment are merging to create a gaming giant, and Bristol-Myers Squibb had some bad news for investors.

Major market benchmarks mostly drifted sideways on low volume Monday, with investors looking forward to trade talks at the G-20 meeting later this week. The Dow Jones Industrial Average (^DJI 1.34%) eked out a tiny gain, but the S&P 500 (^GSPC 2.02%) lost ground.

Today's stock market

Index Percentage Change Point Change
Dow 0.03% 8.41
S&P 500 (0.17%) (5.11)

Data source: Yahoo! Finance.

As for individual stocks, Eldorado Resorts (ERI) is buying Caesars Entertainment (CZR), and Bristol-Myers Squibb (BMY 1.70%) reported some disappointing news.

Colorful collage of graphs.

Image source: Getty Images.

Eldorado bets on Caesars

Eldorado Resorts is buying Caesars Entertainment in a $17 billion cash-and-stock deal, creating the largest owner and operator of gaming assets in the U.S. and sending shares of Caesars up 14.5% to $11.44 and those of El Dorado down 10.6% to $45.77.

Eldorado is acquiring all outstanding shares of Caesars for $12.75 apiece, consisting of $8.40 in cash and 0.0899 shares of Eldorado stock for every share of Caesars. After the transaction, Eldorado shareholders will own about 51% of the combined company. As part of the financing of the deal, VICI Properties will acquire the real estate associated with three casinos and increase rent on other Caesars properties in exchange for $3.2 billion.

The combined entity will own about 60 properties in 16 states. The companies expect to find $500 million in annual cost savings and hope to use the data from Caesars' rewards program to attract guests to properties across the portfolio. The deal was another win for billionaire investor Carl Icahn, who had been pushing Caesars to put itself up for sale.

Bad news comes in threes for Bristol-Myers and Celgene

Bristol-Myers Squibb reported a trifecta of bad news about its pending $74 billion merger with Celgene (CELG) and a drug trial, causing Bristol's shares to fall 7.4% and those of Celgene to drop 5.5%.

Responding to antitrust concerns from the U.S Federal Trade Commission (FTC), Bristol-Myers will be divesting the blockbuster psoriasis drug Otezla, Celgene's third-largest moneymaker and a significant driver of growth for the company. Celgene had recently guided to Otezla sales of $1.9 billion in 2019, representing 18% growth over the prior year. The press release also said that the merger is now expected to close "at the end of 2019 or the beginning of 2020." The companies had previously expected to close in the third quarter.

Separately, Bristol-Myers announced that a late-stage clinical trial of its immunotherapy drug Opdivo for first-line treatment of unresectable hepatocellular carcinoma (HCC) failed to meet its primary endpoint. HCC is the most common form of liver cancer and the fourth most common cause of cancer death worldwide. Opdivo is approved for treating HCC in patients who have previously had chemotherapy, and is also in trials for other lines of therapy for HCC.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$78.22 (1.70%) $1.31
Celgene Corporation Stock Quote
Celgene Corporation
CELG
Caesars Entertainment Corporation Stock Quote
Caesars Entertainment Corporation
CZR
Eldorado Resorts, Inc. Stock Quote
Eldorado Resorts, Inc.
ERI
Dow Jones Industrial Average (Price Return) Stock Quote
Dow Jones Industrial Average (Price Return)
^DJI
$32,654.59 (1.34%) $431.17
S&P 500 Index - Price Return (USD) Stock Quote
S&P 500 Index - Price Return (USD)
^GSPC
$4,088.85 (2.02%) $80.84

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
338%
 
S&P 500 Returns
119%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.